TABLE 1.
Baseline characteristics of study population.
| Low risk group Group 1 | High risk group Normal outcome Group 2 | High risk group Preeclampsia Group 3 | Group 1 vs. 2 | Group 2 vs. 3 | Group 1 vs. 3 | |
| N patients | 169 | 142 | 34 | NA | NA | NA |
| Age (mean; SD) | 30.26; 4.38 | 31.72; 4.26 | 30.91; 3.88 | 0.004 | 0.312 | 0.424 |
| Smoking | 21/169 (12.43%) | 10/142 (7.04%) | 3/34 (8.82%) | 0.114 | 0.721 | 0.552 |
| Raynaud | 11/169 (6.51%) | 10/142 (7.04%) | 3/34 (8.82%) | 0.852 | 0.721 | 0.627 |
| BMI (mean; SD) n = 159 (normal risk)/139 (high risk)/34 (preeclampsia) | 24.75; 5.08 | 27.18; 6.32 | 26.68; 5.91 | 0.000 | 0.674 | 0.052 |
| Length (mean; SD) n = 159 (normal risk)/139 (high risk)/34 (preeclampsia) | 165.2; 6.64 | 166.93; 6.38 | 166.18; 7.17 | 0.022 | 0.547 | 0.440 |
| Weight (mean; SD) n = 169 (normal risk)/141 (high risk)/34 (preeclampsia) | 68.03; 15.14 | 76.94; 18.06 | 75.70; 19.47 | 0.000 | 0.726 | 0.011 |
| Mean Arterial Pressure (mean; SD) = 161 (normal risk)/142 (high risk)/34 (preeclampsia) | 91.42; 8.95£ | 95.32; 11.44 | 104.68; 13.21 | 0.001 | 0.000 | 0.000 |
| Parity | 0.0000¥ | |||||
| Nulliparous | 61.54% | 28.87% | 59.38% | - | - | - |
| Primiparous/multiparous | 38.46% | 71.13% | 40.63% | - | - | - |
| Gestational age at birth (mean; SD) | 39+1.6; 12.44 (days) | 38+6; 22.63 (days) | 35; 22.63 (days) | 0.058 | 0.000 | 0.000 |
| Mode of delivery n = 169 (normal risk)/135 (high risk)/30 (preeclampsia) | 0.247* | |||||
| Vaginal | 81.55% | 74.07% | 73.33% | - | - | - |
| Section | 18.45% | 25.93% | 26.67% | - | - | - |
| Birth Weight in grams (mean; SD) n = 168 (normal risk)/133 (high risk—normal outcome)/29 (high risk—preeclampsia) | 3318.76; 537.87 | 3258.06; 502.37 | 2257.69; 934.91 | 0.318 | 0.000 | 0.000 |
| Percentile (mean; SD) n = 168 (normal risk)/129 (high risk—normal outcome)/29 (high risk—preeclampsia) | 52.12; 29.35 | 49.20; 26.76 | 35.64; 30.67 | 0.378 | 0.018 | 0.006 |
| Medication (other than antihypertensive) | 8.88% | 17.04% | 21.88% | 0.033 | 0.522 | 0.031 |
| Medication (antihypertensive) | 0% | 5.15% | 37.50% | 0.003 | 0.000 | 0.000 |
| Reason for evaluation in high prenatal care outpatient clinic | 0/169 | 142/142 (100%) | 34/34 (100%) | NA | ||
| History of abruption placentae | 2/142 | - | ||||
| History of eclampsia/pre-eclampsia | 47/142 | 6/34 | - | |||
| Pre-eclampsia in current pregnancy | 0/142 | 14/34 | - | |||
| Underlying systemic disease | 10/142 | - | ||||
| Newly discovered hypertension | 27/142 | 9/34 | - | |||
| History of gestational hypertension | 15/142 | 1/34 | - | |||
| History of HELLP | 8/142 | 1/34 | - | |||
| Essential hypertension | 4/142 | 1/34 | - | |||
| History of intra-uterine growth restriction | 8/142 | - | ||||
| Newly discovered intra-uterine growth restriction | 2/142 | - | ||||
| Age | 1/142 | - | ||||
| History of unexplained intrauterine demise | 1/142 | - | ||||
| Profound edema | 1/142 | - | ||||
| Thrombophilia | 2/142 | 2/34 | - | |||
| History of premature rupture of membranes | 3/142 | - | ||||
| Screening of high uterine artery resistance | 9/142 | - | ||||
| History of premature birth | 2/142 | - |
*Vaginal vs. section.
¥Nulliparous vs. primi-/multiparous.
£Based on 161 assessments.
NA, not applicable.
For continuous variables mean and standard deviation are given, together with a p-value obtained for a t-test. For categorical variables counts and % are given, with a p-value for a Chi-square test (or Fisher Exact test).
Bold values are the significant ones.